Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu - PubMed (original) (raw)
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C C Benz et al. Breast Cancer Res Treat. 1992.
Abstract
Since the poor prognosis associated with HER2 amplified breast cancers might be explained by a mechanistic association between p185HER2 overexpression and therapeutic resistance, we assessed the chemo-endocrine sensitivity of estrogen receptor (ER) containing MCF-7 breast cancer cells transfected with full-length HER2 cDNA. Of the 36 isolated MCF/HER2 subclones, 7 were found to overexpress p185HER2 surface receptor at levels 3 to 45-fold greater than parental or control transfected cells (MCF/neo). The overexpressing transfectants possessed increased inositol-1,4,5-triphosphate-3'-kinase activity comparable to enzyme activity in the endogenously HER2 amplified breast cancer cell lines SK-Br-3 and BT-474. The anti-p185HER2 monoclonal antibody and receptor-specific partial agonist, muMAb4D5 (4D5), known to inhibit growth of SK-Br-3 and BT-474 cells, produced no significant growth inhibitory effect on any of the transfectants including the 45-fold overexpressing MCF/HER2-18 cells which were studied in greater detail. MCF/HER2-18 cells contained at least partially functioning exogenous receptor since 4D5 (3 micrograms/ml) specifically stimulated phosphorylation of p185HER2 and its co-precipitating ptyr56 substrate within 5 min, and this was followed at 1 h by a transient induction of c-myc but not c-fos mRNA. ER content and the in vitro sensitivity of MCF/HER2-18 cells to 5-fluorouracil and adriamycin were identical to those of control transfectants and parental cells. However, these highly overexpressing transfectants had acquired low level (2 to 4-fold) resistance to cisplatin and were no longer sensitive to the antiestrogen tamoxifen (TAM). To compare the hormone-dependent tumorigenicity of the HER2 transfectants, MCF/HER2-18 and control cells (MCF, MCF/neo-3) were implanted into ovariectomized athymic nude mice. No tumors were produced in the absence of estradiol (E2) administration. In E2 supplemented mice, MCF/HER2-18 tumors grew most rapidly. When E2 treatment was stopped and daily TAM injections were initiated, MCF-7 and MCF/neo-3 tumor growth ceased immediately, while MCF/HER2-18 tumors continued to show an accelerated growth rate lasting weeks. This pattern of hormone-dependent, TAM-resistant growth exhibited by the MCF/HER2-18 tumors in nude mice supports the possibility that p185HER2 overexpression in human breast cancers may be linked to therapeutic resistance.
Similar articles
- Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C, Gajdos C, Cheng D, Jordan VC. Osipo C, et al. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):249-56. doi: 10.1016/j.jsbmb.2004.12.005. J Steroid Biochem Mol Biol. 2005. PMID: 15860267 - Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Osipo C, et al. Int J Oncol. 2007 Feb;30(2):509-20. Int J Oncol. 2007. PMID: 17203234 - Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A, et al. Shepard HM, et al. J Clin Immunol. 1991 May;11(3):117-27. doi: 10.1007/BF00918679. J Clin Immunol. 1991. PMID: 1679763 Review. - Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H, Arteaga CL. Kurokawa H, et al. Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916237 Review.
Cited by
- Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model.
Pulido-Capiz A, Chimal-Vega B, Avila-Barrientos LP, Campos-Valenzuela A, Díaz-Molina R, Muñiz-Salazar R, Galindo-Hernández O, García-González V. Pulido-Capiz A, et al. Pharmaceutics. 2024 Sep 6;16(9):1179. doi: 10.3390/pharmaceutics16091179. Pharmaceutics. 2024. PMID: 39339215 Free PMC article. - Biochemical Pathways Delivering Distinct Glycosphingolipid Patterns in MDA-MB-231 and MCF-7 Breast Cancer Cells.
Markotić A, Omerović J, Marijan S, Režić-Mužinić N, Čikeš Čulić V. Markotić A, et al. Curr Issues Mol Biol. 2024 Sep 15;46(9):10200-10217. doi: 10.3390/cimb46090608. Curr Issues Mol Biol. 2024. PMID: 39329960 Free PMC article. Review. - The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
O'Neill CE, Sun K, Sundararaman S, Chang JC, Glynn SA. O'Neill CE, et al. Front Physiol. 2024 Mar 27;15:1358850. doi: 10.3389/fphys.2024.1358850. eCollection 2024. Front Physiol. 2024. PMID: 38601214 Free PMC article. Review. - HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?
Tauber N, Cirkel C, Claussen A, Fick F, Kontomanolis E, Krawczyk N, Rody A, Banys-Paluchowski M. Tauber N, et al. Cancers (Basel). 2024 Mar 11;16(6):1121. doi: 10.3390/cancers16061121. Cancers (Basel). 2024. PMID: 38539456 Free PMC article. Review. - Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers.
Sharma T, Zhang Y, Zigrossi A, Cravatt BF, Kastrati I. Sharma T, et al. Breast Cancer Res Treat. 2023 Oct;201(3):561-570. doi: 10.1007/s10549-023-07037-4. Epub 2023 Jul 21. Breast Cancer Res Treat. 2023. PMID: 37477798
References
- Mol Cell Biol. 1989 Mar;9(3):1165-72 - PubMed
- Oncogene. 1989 Aug;4(8):979-84 - PubMed
- Growth Regul. 1991 Jun;1(2):72-82 - PubMed
- J Clin Invest. 1990 Nov;86(5):1632-40 - PubMed
- Br J Cancer. 1992 Jan;65(1):118-21 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous